{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:32:03Z","timestamp":1793172723209,"version":"4.5.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Primary vaginal malignant melanoma is a rare gynecological malignant tumor with high malignancy and poor prognosis. Because of its insidious incidence, it is generally diagnosed in the late stage, and the 5-year survival rate is only 5% to 25%. Due to the rarity of this disease and the limited number of related cases reported in the literature, there is currently no unified standard for its diagnosis and treatment. Therefore, the treatment of this disease has always been a difficult problem in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 56-year-old woman was admitted to our hospital with discomfort in the lower abdomen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>The final diagnosis of this patient was vaginal malignant melanoma (T4N1M0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient underwent extensive hysterectomy, bilateral adnexectomy, pelvic lymph node resection, and total vaginectomy. Following the surgery, the patient received adjuvant chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient was followed up regularly. No recurrence or metastasis has been reported to date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The treatment of primary vaginal malignant melanoma is still dominated by surgery, while radiotherapy and chemotherapy are controversial. Immunotherapy and targeted therapy highlight certain advantages in advanced patients, which still need to be verified by large sample studies, We provide a case of postoperative adjuvant chemotherapy for vaginal malignant melanoma. So far, no signs of disease recurrence have been found. As the price of chemotherapy drugs decreases, it is economically convenient and acceptable for most patients, but its effectiveness needs to be observed in large-scale clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000036128","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T12:09:08Z","timestamp":1708517348000},"page":"e36128","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of primary vaginal malignant melanoma and review of previous literature: A case report"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9937-9466","authenticated-orcid":false,"given":"Suning","family":"Bai","sequence":"first","affiliation":[{"name":"Department of Gynecology, Hebei General Hospital, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Hebei General Hospital, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Hebei General Hospital, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Hebei General Hospital, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/jog.14136","article-title":"Primary malignant melanoma of the uterine cervix or vagina which were successfully treated with nivolumab.","volume":"46","author":"Anko","year":"2020","journal-title":"J Obstet Gynaecol Res"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.4103\/jcrt.JCRT_893_15","article-title":"Primary vaginal malignant melanoma: a rare entity with review of literature.","volume":"15","author":"Puri","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"702287","DOI":"10.3389\/fonc.2021.702287","article-title":"Mucosal melanoma: pathological evolution, pathway dependency and targeted therapy.","volume":"11","author":"Ma","year":"2021","journal-title":"Front Oncol"},{"key":"R4-20250503","first-page":"4017","article-title":"Primary malignant melanomas of the female lower genital tract: clinicopathological characteristics and management.","volume":"10","author":"Wang","year":"2020","journal-title":"Am J Cancer Res"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3390\/biomedicines9070758","article-title":"Vulvar and vaginal melanomas\u2014the darker shades of gynecological cancers.","volume":"9","author":"Dobric\u0103","year":"2021","journal-title":"Biomedicines"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(08)70254-7","article-title":"Management of primary melanoma of the female urogenital tract.","volume":"9","author":"Piura","year":"2008","journal-title":"Lancet Oncol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1158\/1078-0432.CCR-13-0739","article-title":"Phase II randomized trial comparing high-dose IFN-\u03b12b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.","volume":"19","author":"Lian","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/IGC.0000000000000013","article-title":"Primary malignant melanoma of the vagina: a retrospective clinicopathologic study of 44 cases.","volume":"24","author":"Xia","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2019.11.015","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment \u2013 update 2019.","volume":"126","author":"Garbe","year":"2020","journal-title":"Eur J Cancer"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.3747\/co.27.5933","article-title":"Systemic adjuvant therapy for adult patients at high risk for recurrent cutaneous or mucosal melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.","volume":"27","author":"Petrella","year":"2020","journal-title":"Curr Oncol"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic therapy for melanoma: ASCO guideline.","volume":"38","author":"Seth","year":"2020","journal-title":"J Clin Oncol"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3892\/ol.2022.13550","article-title":"Primary vaginal malignant melanoma successfully treated with combination therapy: a case report.","volume":"24","author":"Yin","year":"2022","journal-title":"Oncol Lett"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"e25691","DOI":"10.1097\/MD.0000000000025691","article-title":"Primary vaginal malignant melanoma: a rare case report of successful treatment with nivolumab.","volume":"100","author":"Guo","year":"2021","journal-title":"Medicine (Baltim)"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma.","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/annonc\/mdx079","article-title":"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.","volume":"28","author":"Guo","year":"2017","journal-title":"Ann Oncol"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"103564","DOI":"10.1016\/j.critrevonc.2021.103564","article-title":"Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.","volume":"169","author":"Awada","year":"2022","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:26:40Z","timestamp":1746304000000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":16,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036128","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]}}}